Gilead Sciences (GILD) analysis

Loading the Vaultflake…

Health is the debt of two books, antiviral and oncology, not of a patent that lasts forever. Quality separates the HIV margin from hepatitis and from oncology. Growth follows covered treatments, not a hepatitis year. P/E is read against a year of many antiviral sales, not against that peak. Shareholder return is the dividend, checked against cash. Do not read it as the treatment already written into the guideline.

The P/E of a year of many antiviral sales is not the earnings if the payer cuts back. EV/EBITDA is read without treating hepatitis as if it repeated every year. Do not use Amgen's multiple, which sells other biologics, as if the antiviral and that catalog were the same book. A dash if GILD is missing.

Limits of this report

Not advice on Gilead. Vaultflake does not describe the medicine or how it is given, and does not state the patent date. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report